FDA-Approved Synthetic THC Trials Show 21% Tic Reduction In Tourette Syndrome Patients

SciSparc Ltd. SPRC, a clinical-stage pharmaceutical company, reported a new Phase IIb trial of SCI-110, a proprietary THC-based medication for Tourette Syndrome (TS) treatment. Spanning across renowned institutions such as Yale University, Tel Aviv Sourasky Medical Center and Hannover Medical…#scisparcltd #thc #yaleuniversity #bfarm #sci110 #fda #scisparc #asd #amazon
Source: Reuters: Health - Category: Consumer Health News Source Type: news